Trial Profile
Prospective correlative study of FDG-PET SUV and proteomic profile (VeriStrat) of Non Small Cell Lung Cancer (NSCLC) patients treated with erlotinib
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 Dec 2015
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Antineoplastics
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 23 Dec 2015 New trial record